share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K:外国发行人报告
美股SEC公告 ·  08/30 17:04

Moomoo AI 已提取核心信息

On August 30, 2024, NeuroSense Therapeutics Ltd., a clinical-stage biotech company, announced that it received a Nasdaq Minimum Bid Price Notification. The company's shares had closed below the required $1.00 minimum bid price for 30 consecutive trading days, violating Nasdaq Listing Rules. Despite the notice, NeuroSense's shares will continue to trade on the Nasdaq Capital Market under the symbol 'NRSN' during the 180-day grace period ending on February 24, 2025. The company must boost its share price to at least $1.00 for 10 consecutive business days before this deadline to regain compliance. If compliance is not achieved, NeuroSense may be granted an additional 180 days if it meets other listing standards. The company's operations remain unaffected by this notification, and it is actively monitoring its share price to address the deficiency within the compliance period. NeuroSense specializes in developing treatments for neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's disease.
On August 30, 2024, NeuroSense Therapeutics Ltd., a clinical-stage biotech company, announced that it received a Nasdaq Minimum Bid Price Notification. The company's shares had closed below the required $1.00 minimum bid price for 30 consecutive trading days, violating Nasdaq Listing Rules. Despite the notice, NeuroSense's shares will continue to trade on the Nasdaq Capital Market under the symbol 'NRSN' during the 180-day grace period ending on February 24, 2025. The company must boost its share price to at least $1.00 for 10 consecutive business days before this deadline to regain compliance. If compliance is not achieved, NeuroSense may be granted an additional 180 days if it meets other listing standards. The company's operations remain unaffected by this notification, and it is actively monitoring its share price to address the deficiency within the compliance period. NeuroSense specializes in developing treatments for neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's disease.
2024年8月30日,临床阶段生物技术公司神经感知治疗有限公司宣布收到纳斯达克最低买盘价格通知。该公司股票收盘价连续30个交易日低于所需的1.00美元的最低买盘价格,违反了纳斯达克上市规则。尽管收到通知,神经感知的股票将继续在2025年2月24日结束的为期180天的宽限期内以“NRSN”标的在纳斯达克资本市场交易。在此期限之前,该公司必须使股票价格连续10个工作日至少达到1.00美元以恢复合规。如果未达到合规要求,如果符合其他上市标准,神经感知可能会被授予额外的180天。该公司的业务对此通知未受影响,并且正在积极监控股票价格以在合规期内解决不足。神经感知专门致力于开发针对神经退行性疾病,如肌萎缩性侧索硬化症、阿尔茨海默病和帕金森病的治疗。
2024年8月30日,临床阶段生物技术公司神经感知治疗有限公司宣布收到纳斯达克最低买盘价格通知。该公司股票收盘价连续30个交易日低于所需的1.00美元的最低买盘价格,违反了纳斯达克上市规则。尽管收到通知,神经感知的股票将继续在2025年2月24日结束的为期180天的宽限期内以“NRSN”标的在纳斯达克资本市场交易。在此期限之前,该公司必须使股票价格连续10个工作日至少达到1.00美元以恢复合规。如果未达到合规要求,如果符合其他上市标准,神经感知可能会被授予额外的180天。该公司的业务对此通知未受影响,并且正在积极监控股票价格以在合规期内解决不足。神经感知专门致力于开发针对神经退行性疾病,如肌萎缩性侧索硬化症、阿尔茨海默病和帕金森病的治疗。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息